Every company that reaches the Nasdaq bell walks the same 90-day blocks in the final year: SEC comment letters, roadshow, pricing, allocation. But the year before that year is where the winners are sorted from the also-rans. The Robinhood 18-month pathway compresses that pre-year into four phases we run against every founder we underwrite: diagnostic, structuring, filing, listing. Here is what each phase actually requires.
TL;DR
- The 18-month pathway is not a marketing timeline. It is the sequence a competent Nasdaq listing actually requires.
- Diagnostic (months 1-3) covers cap table, PCAOB audit access, incorporation, board reality, and listing intent.
- Structuring (months 4-9) is where PCAOB audit history gets built, corporate governance gets installed, and the F-1 or S-1 outline is drafted.
- Filing (months 10-15) covers SEC review, comment letters, financial refresh, and roadshow prep.
- Listing (months 16-18) is bell, allocation, and the first two quarters of post-IPO discipline.
- Compressing this timeline is possible. Compressing the diagnostic is where deals fail.
Not twelve. Not twenty-four.
Founders often ask why the Nasdaq pathway cannot be compressed to twelve months. The honest answer is that it can be, in narrow circumstances, and the founders who ask this question are usually not in those circumstances. The eighteen-month figure is not conservative padding. It is what happens when four phases run at their natural pace and are not asked to overlap.
The SEC's own review cycle drives part of the shape. From F-1 or S-1 initial filing through effectiveness, the comment-letter dance usually takes four to six months in a well-prepared filing and eight to ten in a poorly prepared one. PCAOB audit history, if it does not already exist, cannot be manufactured; it has to be built one fiscal quarter at a time. Board governance capable of surviving analyst scrutiny cannot be installed in the two weeks before roadshow. Each of these has a floor. Eighteen months is what those floors add up to when you sequence them properly.
For a specialist deep-dive on the phase shape and what each month contains, see The 18-Month Listing Shape by Amanda Ooi.
Months 1-3. Five questions.
The diagnostic phase is deceptively named. It sounds like a formality, a checklist before the real work begins. It is not. This is the phase in which the most consequential decisions of the whole pathway get made, and it is the phase most likely to be truncated by founders who mistake urgency for progress.
Cynthia Ng walks every founder through five questions before we underwrite: cap table cleanliness, PCAOB audit access, incorporation and intellectual property, board reality, listing intent. Each of these has a specific meaning in the diagnostic context and a specific pass-fail bar. Getting any of them wrong at this stage almost always resurfaces the issue eight months later during SEC comment-letter review, at ten times the cost.
See The Corporate Doctor Diagnostic: Five Questions by Cynthia Ng for the full framework.
Deals that skip the diagnostic phase almost always resurface those questions later during SEC comment-letter review, at ten times the cost.
Months 4-9. Building the audit.
Structuring is where the company becomes technically listable. This is the phase most heavily front-loaded with third-party dependencies: PCAOB-registered auditor engagement, US securities counsel, local counsel, corporate secretariat, and often the reincorporation or restructuring work that the diagnostic identified.
The PCAOB audit transition is the single most time-consuming workstream. The auditor needs to cover the two or three fiscal years shown in the F-1 or S-1, which means the audit history has to be built during structuring rather than filed for at the last minute. Companies that begin the PCAOB audit late are the most common cause of pathway slippage. We have seen deals slip six months over a fiscal quarter that was not properly audited in time.
In parallel, corporate governance gets installed: independent directors, audit committee, compensation committee, insider trading policy, whistleblower channels. Cap table hygiene work — often including cleanup of legacy convertible instruments, warrant overhangs, or employee option pools — happens in this window. And the F-1 or S-1 outline gets drafted with securities counsel, with the disclosure architecture set here even though the document itself is not filed until phase 3.
Months 10-15. The comment-letter dance.
Filing is the phase most visible from outside the pathway and the phase where the most measurable milestones happen. The F-1 or S-1 is filed with the SEC. Comment letters arrive on a roughly six-to-eight-week cadence. Each letter contains between fifteen and forty comments ranging from single-word disclosure clarifications to substantive rework requests. The company, its counsel, and its auditors respond, refile, and wait for the next round.
Most deals close out comments in three to five rounds. Underprepared filings run to seven or eight rounds and slip out of the pricing window they had planned for. Well-prepared filings finish comment cycles in month 14, complete their financial refresh (typically an updated set of unaudited interim financials at least as recent as the most recent completed quarter), and enter roadshow prep in month 15.
Roadshow itself is compressed: two to three weeks of institutional investor meetings across US and Asia, coordinated with the underwriter's syndicate desk. Retail allocation, if applicable, gets structured in parallel. Pricing happens the night before listing.
Months 16-18. The bell is the start.
The bell rings on day one of month 16. Everything from that moment onward is post-IPO. Founders consistently underestimate what the first four quarters as a listed issuer actually require.
Quarterly earnings on a repeatable cadence, with disclosures signed off through an audit committee process the company built during structuring. Insider trading windows opening and closing on schedule around each earnings release. 6-K and 8-K filings for material events. Analyst coverage relationships, initiated during roadshow, converted into a working IR function. Board processes that turn a founder-controlled operating rhythm into a governance-controlled quarterly rhythm.
Robinhood stays engaged through the first four quarters as part of the pathway. For the fuller playbook on what post-IPO governance looks like in practice, see Post-IPO Governance Playbook by Cynthia Ng.
What founders actually ask.
Why does the Nasdaq listing pathway take 18 months?
The 18-month timeline is what a competent Nasdaq listing actually requires when the four phases are run sequentially: diagnostic (months 1-3), structuring plus PCAOB audit history (months 4-9), SEC filing and review (months 10-15), and listing plus post-IPO discipline (months 16-18). Compressing the timeline is possible in narrow circumstances, but the shortcuts almost always come out of the diagnostic phase, and the diagnostic phase is where the most valuable work happens.
What happens in the diagnostic phase of the listing pathway?
The diagnostic phase runs months 1 to 3 and covers five questions: cap table cleanliness, PCAOB audit access, incorporation and intellectual property, board reality, and listing intent. This is the phase where Robinhood decides whether to underwrite the company and where the founder decides whether Nasdaq is the right venue. Deals that skip the diagnostic almost always resurface those questions later during SEC review, at ten times the cost.
When does the PCAOB audit start in the listing pathway?
The transition to a PCAOB-registered audit firm typically begins in month 4, at the start of the structuring phase. The audit needs to cover the two or three fiscal years shown in the F-1 or S-1 filing, so the audit history has to be built during structuring rather than filed for at the last minute. Companies that begin the PCAOB audit late are the most common cause of pathway slippage.
How much does an 18-month Nasdaq listing pathway cost?
Total costs vary meaningfully by company size, complexity, and jurisdiction, but a working range for a mid-market Asian issuer is USD 2 million to USD 5 million across auditor, US securities counsel, local counsel, underwriter fees, exchange fees, D&O insurance, and investor relations. Robinhood's compensation for structuring and running the engagement is on the cap table, not on retainer.
What happens after the bell rings?
The listing is not the end. The first four quarters as a listed issuer require a governance and disclosure discipline that many founders underestimate. Quarterly earnings, 6-K and 8-K filings, insider trading windows, analyst coverage management, and board processes all have to work from day one. Robinhood stays engaged through the first four quarters as part of the pathway.
Read the full analysis.
When you are ready to start the diagnostic.
Robinhood Ventures commits its own capital first, then activates corporate execution. If you are exploring a Nasdaq listing and want to start with the diagnostic phase, the corporate engagement page walks through what working together looks like.